ENDPOINTS 4.1. PRIMARY EFFICACY ENDPOINTS The primary efficacy endpoints are identical for both Stage 1 and Stage 2 of the trial. Primary efficacy endpoints include:  OS-12—the percentage of patients surviving at 12 months after the initiation of SL-701 therapy. The primary efficacy analysis for either stage will be to compare the lower bound of a 2-sided 95% Clopper Exact confidence interval (CI) surrounding the observed OS-12 rate to a value of 20%. Statistical significance will be determined if the lower bound of this CI ≥20%. 4.2. SECONDARY EFFICACY ENDPOINTS The secondary efficacy endpoints are identical for Stage 1 and Stage 2 of the trial. The secondary efficacy endpoints include the following:  ORR —the percentage of patients whose best response is either complete response (CR) or partial response (PR) documented on 2 consecutive MRIs ≥ 4 weeks apart by modified RANO criteria (Wen 2010, Appendix 2).  Disease control rate- the percentage of patients whose best response is either complete response (CR), partial response (PR) or stable disease (SD) documented on 2 consecutiv e MRIs ≥ 4 weeks apart by modified RANO criteria (Wen 2010, Appendix 2)  Duration of response ( DR)—the time in months between the date at which measurement criteria are first met for objective response (ie, CR or PR), whichever is first recorded, unt il the earliest date at which PD is documented by modified RANO criteria (Wen 2010, Appendix 2) or the date of death in the absence of disease progression.  Duration of disease control ( DDC )- the time in months between the date of first dose of SL-701 until the earliest date at which PD is documented by modified RANO criteria (Wen 2010, Appendix 2) or the date of death in the absence of disease progression  Progression-free survival ( PFS)—the time in months from initiation of SL-701 therapy to the first documentation of PD by modified RANO criteria (Wen 2010, Appendix 2) or death from any cause, whichever occurs first.  Overall survival (OS) —the time in months from the date of initiation of SL-701 therapy to the date of death from any cause. 4.3. EXPLORATORY ENDPOINT S  Estimate the relationship between ORR and disease control to overall survival DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 20 of 63  Comparison of respon se-based measures as assessed by modified RANO criteria and RECIST (version 1.1) and correlation between responses and OS. 4.4. SAFETY ENDPOINTS The primary safety endpoints are, among the first 24 patients treated for each study Stage (1 and 2) :  Regimen limiting toxicity (RLT).  Sudden or unexpected deaths related to SL-701 or, in Stage 2, SL-701 in combination with bevacizumab. The secondary safety endpoints in all treated patients include:  Adverse events (AEs)  Serious adverse events (SAEs)  Physical examinations  Vital signs (heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure)  Body weight  Clinical laboratory evaluations (hematology, serum chemistry, coagulation parameters, urinalysis)  Reasons for discontinuation of study treatment DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 21 of 63 5.